Onco Wiki / Enfermedad

Tumor neuroendocrino pancreático (pNET), G1/G2 bien diferenciado

Vista determinista de la entidad fuente YAML. La autoridad clínica sigue con los ID de fuente citados y estado de firma del revisor.

IDDIS-PNET
TipoEnfermedad
Aliaces
PNET funcional (insulinoma, gastrinoma, glucagonoma, VIPoma)Non-functional pNETTumor de células de islotes pancreáticasTumor neuroendocrino pancreáticoPNETНейроендокринна пухлина підшлункової залози (пНЕП), добре-диференційована G1/G2
Situaciónreviewed 2026-05-03 | pending_clinical_signoff
EnfermedadesNinguna declarada
FuentesSRC-NCCN-NET-2025

Informational support. All recommendations must be verified by a qualified oncologist. Engineering checks are not clinical validation or treatment approval.

Fuente YAML

icd_o_3_morphology8240/3
icd_o_3_topography["C25"]
icd_10C25.4
who_classificationWHO Classification of Digestive System Tumours 5th ed (2019): Pancreatic neuroendocrine tumour G1 (Ki67 <3%), G2 (3–20%), G3 (>20% but well-differentiated)

Capacidades

Notas

Well-differentiated pNET G1/G2 is the dominant subtype in clinical practice (non-functional, discovered incidentally or via abdominal mass/liver mets). Grading per WHO 2019: G1 Ki67 <3%, G2 Ki67 3–20%. G3 well-differentiated pNET (Ki67 >20%) occupies a grey zone — still well-differentiated morphologically but higher proliferation; NCCN recommends everolimus/sunitinib/SSA ± chemo; not modelled separately here (flagged via RF-NET-HIGH-GRADE-G3 for MDT review). Distinguishing from poorly differentiated NEC (ICD-O 8246/3) is essential: NEC requires platinum-etoposide chemotherapy (not SSA/TKI/mTOR). Key trials: RADIANT-3 (everolimus, Yao NEJM 2011), Raymond 2011 (sunitinib), CLARINET pNET subgroup (lanreotide). Surgery remains the only curative option for localized disease.

Utilizado por

Relevancia terapéutica

Algoritmos

Enfermedad

Indicación

Procedimientos

Cuestionarios

Señal de alerta

Fuentes